Pfizer announced a multi-year agreement with Gilead Sciences, to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of the multiple external manufacturing organizations supporting efforts to scale up the supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.
In March, Pfizer launched a five-point plan, which called on all members of the innovation ecosystem – from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions – to commit to addressing the dire Covid-19 crisis.
“From the beginning, it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis. Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions,” said Albert Bourla, chairman and chief executive officer. “Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics, and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead uses our manufacturing capacity to help facilitate the supply of this medicine to patients as quickly as possible.”
